Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2002 Jul 15;2:17.
doi: 10.1186/1471-230x-2-17.

Are Proton Pump Inhibitors the First Choice for Acute Treatment of Gastric Ulcers? A Meta Analysis of Randomized Clinical Trials

Affiliations
Free PMC article
Meta-Analysis

Are Proton Pump Inhibitors the First Choice for Acute Treatment of Gastric Ulcers? A Meta Analysis of Randomized Clinical Trials

Maribel Salas et al. BMC Gastroenterol. .
Free PMC article

Abstract

Background: Gastric ulcers are a frequent problem in the United States. Proton pump inhibitors have been shown to increase healing rates and improve clinical symptoms. The objective of this study is to compare gastric ulcer healing rates for patients treated with a proton pump inhibitor (PPI) (omeprazole, rabeprazole, pantoprazole, or lansoprazole), an histamine 2- receptor antagonist (ranitidine) or placebo.

Methods: A literature search was conducted to identify randomized, controlled clinical trials that included a PPI in at least one treatment arm and assessed the gastric ulcer healing rates endoscopically. The healing rates were estimated for each treatment at specific time points, and Rate Ratios (RR) and 95% confidence intervals (CI) were estimated for each trial.

Results: Sixteen trials met the inclusion criteria: four compared a PPI versus placebo, nine compared a PPI versus ranitidine (no trials of rabeprazole versus ranitidine met the inclusion criteria), and three compared a newer PPI (lansoprazole, pantoprazole or rabeprazole) versus omeprazole. In relation to ranitidine, the pooled RR of PPIs (lansoprazole, omeprazole and pantoprazole) was 1.33 (95% CI 1.24 to 1.42) at four weeks. In each trial, greater improvement in the studied clinical symptoms was found with the newer PPIs (rabeprazole, pantoprazole and lansoprazole) when compared to omeprazole.

Conclusion: In this study treatment with PPIs resulted in higher healing rates than ranitidine or placebo. This evidence suggests that the first choice for gastric ulcer treatment for the greater relief of symptoms is one of the newer PPIs.

Figures

Figure 1
Figure 1
Overall healing rate ratios and 95% CI of different proton pump inhibitors versus omeprazole or ranitidine
Figure 2
Figure 2
Healing rate ratios at four weeks versus sample size to explore publication bias

Similar articles

See all similar articles

Cited by 13 articles

See all "Cited by" articles

References

    1. Kurata JH, Haile BM. Epidemiology of peptic ulcer disease. Clin Gastroenterol. 1984;13:289–307. - PubMed
    1. Florent C. Progress with proton pump inhibitors in acid peptic disease: treatment of duodenal and gastric ulcer. Clin Ther. 1993;15:14–21. - PubMed
    1. Hasebe T, Harasawa S, Miwa T. Factors affecting depth of gastric ulcers. Tokai J Exp Clin Med. 1998;23:177–182. - PubMed
    1. Sontag SJ. Guilty as charged: bugs and drugs in gastric ulcer. Am J Gastroenterol. 1997;92:1255–1261. - PubMed
    1. Hasebe T, Harasawa S, Miwa T. Factors affecting depth of gastric ulcers. Tokai J Exp Clin Med. 1998;23:177–182. - PubMed

Publication types

MeSH terms

LinkOut - more resources

Feedback